Cited by 370Bone Metabolism and DiseasesBone health and osteoporosis researchRheumatoid Arthritis Research and Therapies

LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption

Luo, Jian, Yang, Zhengfeng, Ma, Yu, Yue, Zhiying, Lin, Hongyu, Qu, Guojun, Huang, Jinping, Dai, Wentao +11 more·2016·Nature Medicine

Abstract

Tumor necrosis factor (TNF) superfamily member 11 (TNFSF11, also known as RANKL) regulates multiple physiological or pathological functions, including osteoclast differentiation and osteoporosis. TNFRSF11A (also called RANK) is considered to be the sole receptor for RANKL. Herein we report that leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4, also called GPR48) is another receptor for RANKL. LGR4 competes with RANK to bind RANKL and suppresses canonical RANK signaling during osteoclast differentiation. RANKL binding to LGR4 activates the Gαq and GSK3-β signaling pathway, an action that suppresses the expression and activity of nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1 (NFATC1) during osteoclastogenesis. Both whole-body (Lgr4(-/-)) and monocyte conditional knockout mice of Lgr4 (Lgr4 CKO) exhibit osteoclast hyperactivation (including elevation of osteoclast number, surface area, and size) and increased bone erosion. The soluble LGR4 extracellular domain (ECD) binds RANKL and inhibits osteoclast differentiation in vivo. Moreover, LGR4-ECD therapeutically abrogated RANKL-induced bone loss in three mouse models of osteoporosis. Therefore, LGR4 acts as a second RANKL receptor that negatively regulates osteoclast differentiation and bone resorption.

Integrity signals

Registry

Crossref · 10.1038/nm.4076

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The extracellular domain of LGR4 binds RANKL and inhibits NFATC1 expression, blocking osteoclastogenesis.

    “The extracellular domain of LGR4 binds RANKL and inhibits NFATC1 expression, thus blocking osteoclastogenesis.172”
  • The balance among RANK, RANKL, OPG, and LGR4 fine tunes bone resorption in bone remodeling, and pharmacological modulation of this balance has critical therapeutic potential in osteoporosis.

    “The balance achieved among RANK, RANKL, OPG, and LGR4 fine tunes bone resorption in the bone remodeling process, and the pharmacological modulation of this balance has critical therapeutic potential in osteoporosis.172”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Luo, J., Yang, Z., Ma, Y., Yue, Z., Lin, H., Qu, G., Huang, J., Dai, W., Li, C., Zheng, C., Xu, L., Chen, H., Wang, J., Li, D., Siwko, S., Penninger, J. M., Ning, G., Xiao, J., & Liu, M.
Affiliations
  • Shanghai Changzheng Hospital (CN)
  • Shanghai Academy of Science & Technology (CN)
  • Shanghai Jiao Tong University (CN)
  • Texas A&M University (US)
  • Institute of Molecular Biotechnology (AT)
  • Second Military Medical University (CN)
Corresponding author
  • Luo, Jian
  • Xiao, Jianru
  • Liu, Mingyao
Venue
Nature Medicine
Published
2016-04-11
Volume
22
Issue
5
Pages
539-546
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2330722106
Cited by
370
References
45
Citations by year
2026: 21 · 2025: 25 · 2024: 37 · 2023: 38 · 2022: 51 · 2021: 37 · 2020: 47 · 2019: 35 · 2018: 33 · 2017: 36 · 2016: 10
FWCI
19.76
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
LGR4, RANKL, RANK, osteoclastogenesis, bone resorption, osteoporosis, NFATc1, Gαq signaling, receptor competition, bone erosion
MeSH terms
RAW 264.7 Cells, Glycogen Synthase Kinase 3 beta, Animals, Bone Resorption, Calcium, Cells, Cultured, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Leukocytes, Mononuclear, Osteogenesis, Osteoporosis, Blotting, Western, Signal Transduction, Bone Remodeling, Giant Cell Tumor of Bone, Mice, Knockout, Surface Plasmon Resonance, Receptors, G-Protein-Coupled, GTP-Binding Protein alpha Subunits, Gq-G11, Chromatin Immunoprecipitation, Immunoprecipitation, NFATC Transcription Factors, Mice, RANK Ligand, X-Ray Microtomography, HEK293 Cells, Real-Time Polymerase Chain Reaction, Optical Imaging, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review